Immunic Stock Today
| IMUX Stock | USD 0.62 0.01 2.46% |
PerformanceWeakest
| Odds Of DistressLow
|
Immunic is trading at 0.625 as of the 31st of January 2026; that is 2.46 percent increase since the beginning of the trading day. The stock's open price was 0.61. Immunic has less than a 10 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 2nd of November 2025 and ending today, the 31st of January 2026. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 17th of April 2014 | Category Healthcare | Classification Health Care |
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. t and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. The company has 120.28 M outstanding shares of which 7.09 M shares are currently shorted by private and institutional investors with about 4.19 trading days to cover. More on Immunic
Moving together with Immunic Stock
| 0.83 | EVGN | Evogene | PairCorr |
| 0.68 | IMNN | Imunon Inc | PairCorr |
| 0.68 | IPHA | Innate Pharma | PairCorr |
| 0.76 | MBIO | Mustang Bio | PairCorr |
Moving against Immunic Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Immunic Stock Highlights
| President CEO, Director | Daniel Vitt | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsImmunic utilizes debt financing to potentially enhance returns on invested capital. The relationship between total debt and total assets provides valuable insight into Immunic's leverage profile, showing how much of Immunic's resources are funded through borrowing.
| |||||
Immunic (IMUX) is traded on NASDAQ Exchange in USA and employs 90 people. Immunic is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 73.37 M. Immunic conducts business under Biotechnology sector and is part of Health Care industry. The entity has 120.28 M outstanding shares of which 7.09 M shares are currently shorted by private and institutional investors with about 4.19 trading days to cover.
Immunic currently holds about 72.77 M in cash with (84.77 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.85, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Immunic Probability Of Bankruptcy
Ownership AllocationImmunic has a total of 120.28 Million outstanding shares. 30% of Immunic outstanding shares are owned by outside corporations. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Immunic Ownership Details
Immunic Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Ikarian Capital, Llc | 2025-06-30 | 914.2 K | |
| Ghisallo Capital Management Llc | 2025-06-30 | 835 K | |
| Blackrock Inc | 2025-06-30 | 698.7 K | |
| Rtw Investments, Llc | 2025-06-30 | 402.1 K | |
| Ubs Group Ag | 2025-06-30 | 376.1 K | |
| State Street Corp | 2025-06-30 | 331.9 K | |
| Northern Trust Corp | 2025-06-30 | 258.3 K | |
| Boothbay Fund Management, Llc | 2025-06-30 | 240.9 K | |
| Renaissance Technologies Corp | 2025-06-30 | 132.2 K | |
| Aberdeen Group Plc | 2025-06-30 | 8.2 M | |
| Bvf Inc | 2025-06-30 | 7.7 M |
Immunic Historical Income Statement
Immunic Stock Against Markets
Immunic Corporate Management
| Patrick Walsh | Chief Officer | Profile | |
| Glenn CPA | Chief Officer | Profile | |
| Andreas MD | Chief Officer | Profile | |
| Inderpal Singh | General Counsel | Profile | |
| Jessica Breu | Head Communications | Profile |
Additional Tools for Immunic Stock Analysis
When running Immunic's price analysis, check to measure Immunic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunic is operating at the current time. Most of Immunic's value examination focuses on studying past and present price action to predict the probability of Immunic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunic's price. Additionally, you may evaluate how the addition of Immunic to your portfolios can decrease your overall portfolio volatility.